Clinical trials: Dengue
Dengue, Vector Borne Diseases
Sustainable Reduction of Dengue in Colombia: Vector Breeding Site Intervention With an Insecticidal Coating
Effective control of Aedes aegypti mosquitoes in breeding sites with high reproductive rates could have a major impact on reducing arbovirosis in endemic communities.
- Conditions
- Dengue, Vector Borne Diseases, Arbovirus Infections, Zika
- Trial name
- NCT06268691
- Testing
- Insecticide Coating INESFLY
- Where
- 2 sites in Colombia, Germany
- Volunteers
- 35,000 people, healthy volunteers welcome
- Sponsor
- Rocio Cardenas Sanchez
Dengue Fever
A Study to Monitor the Adverse Events of QDENGA Vaccine in Participants in Malaysia
The main aim of this study is to collect the number and type of medical problems (adverse events) after vaccination with QDENGA in Malaysia and to learn more about such medical problems after vaccination.
- Trial name
- PRIME-Q (NCT06388785)
- Testing
- No Intervention
- Where
- 2 sites in Malaysia
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Takeda
Dengue Fever, Pleural Effusion
Ketotifen as a Treatment for Vascular Leakage During Dengue Fever
Rationale and Aims: Infection by dengue virus (DENV) causes major morbidity and mortality throughout the world. In 2012, an estimated 3.6 billion people live in areas at risk for DENV infection, including Singapore.
- Trial name
- KETODEN (NCT02673840)
- Testing
- Ketotifen
- Where
- 2 sites in Singapore
- Volunteers
- 110 people
- Sponsor
- National University Hospital, Singapore
Dengue
Follow-up the Health Condition , Investigation of the Immuno-regulation , and the Study for Interaction of Viral Hepatitis--- Among Patients With or After Dengue Fever Infection
Originally test host's to understand the tracking healthily and immune change of the dengue fever in Taiwan. Blood drawing 20 c.c for liver examination, kidney and other biochemical function, analyze host immunity adjusts and…
- Trial name
- NCT00629356
- Testing
- dengue fever
- Where
- Taiwan
- Volunteers
- healthy volunteers welcome
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Dengue
Phase II Trial to Evaluate Safety and Immunogenicity of a Dengue 1,2,3,4 (Attenuated) Vaccine
This is a phase II step-wise, randomized, multicenter, double-blind and controlled clinical trial to evaluate the safety and immunogenicity of a attenuated tetravalent lyophilized dengue vaccine manufactured by Butantan…
- Trial name
- NCT01696422
- Testing
- Dengue 1,2,3,4 (attenuated) vaccine, TetraVax-DV Vaccine - Admixture TV003
- Where
- 2 sites in Brazil
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Butantan Institute
Healthy
Study to Investigate the Safety and Immunogenicity of a Tetravalent Chimeric Dengue Vaccine in Healthy Volunteers Between the Ages of 1.5 - 45 Years
The purpose of this study is to assess the safety of Takeda's tetravalent dengue vaccine (TDV) (previously DENVax) administered subcutaneously in healthy adults and children.
- Trial name
- NCT01511250
- Testing
- TDV
- Where
- 8 sites in Colombia, Puerto Rico and 2 more
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- Takeda
Dengue Fever
International Research Consortium on Dengue Risk Assessment, Management, and Surveillance
Improvements in diagnosis of dengue fever and prediction of which patients will get more severe disease are urgently needed to improve the treatment of patients with dengue.
- Trial name
- IDAMS (NCT01550016)
- Testing
- Observation
- Where
- 9 sites in Bangladesh, Brazil and 6 more
- Volunteers
- 7,411 people
- Sponsor
- University of Heidelberg Medical Center
Dengue
Safety and Immunogenicity of the Dengue Virus Vaccine TV005 (TetraVax-DV TV005) in Healthy Adults, Adolescents, and Children in Dhaka, Bangladesh
The purpose of this study is to evaluate the safety and immunogenicity of the recombinant live attenuated tetravalent dengue virus vaccine admixture TV005 (TetraVax-DV T005) in healthy adults, adolescents, and children in Dhaka…
- Trial name
- NCT02678455
- Testing
- TV005 vaccine
- Where
- Bangladesh
- Volunteers
- 192 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Dengue
Impact of Project Wolbachia - Singapore on Dengue Incidence
The study is a cluster-randomised controlled trial set in Singapore, to assess if the deployment of male Wolbachia-infected Aedes aegypti mosquitoes can reduce dengue incidence in intervention clusters.
- Trial name
- NCT05505682
- Testing
- Biological (Male Wolbachia-infected Aedes aegypti)
- Where
- Singapore
- Volunteers
- 724,428 people
- Sponsor
- National Environment Agency, Singapore
Dengue
Effectiveness of a Online Education Material to Improve Dengue Knowledge and Health-Seeking Intention
Dengue is an endemic infectious disease in Malaysia. Delays in seeking treatment and improper self-care contribute to dengue complications and mortality.
- Trial name
- NCT05661877
- Testing
- DengueAid mobile application, MyHealth website
- Where
- Malaysia
- Volunteers
- 116 people, healthy volunteers welcome
- Sponsor
- University of Malaya
Dengue Fever
A Two-dose Primary Vaccination Study of a Tetravalent Dengue Virus Purified Inactivated Vaccine vs. Placebo in Healthy Adults
The study is designed to afford a safety and immunogenicity assessment of three Tetravalent Dengue Virus-Purified Inactivated Vaccine(TDENV-PIV) vaccine candidates.
- Trial name
- DPIV-001 (NCT01666652)
- Testing
- 4 µg TDENV-PIV with Alum adjuvant, 1 µg TDENV-PIV with AS03B1 adjuvant, Phosphate buffered saline
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
DENV-3 Controlled Human Infection Model
A Study to Evaluate the Safety and Efficacy of AV-1 Against Dengue Virus 3 (DENV-3) Infection
The goal of this clinical trial is to determine the prophylactic and therapeutic effect of AV-1 in healthy adults using a DENV-3 controlled human infection model (CHIM)
- Trial name
- NCT06799741
- Testing
- AV-1 100 mg, AV-1 300 mg, AV-1 900 mg
- Where
- 3 sites in United States
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- AbViro LLC
Dengue, Zika
Testing Combined IIT-SIT to Control Mosquito-Borne Diseases At Scale
Mosquito-borne diseases cause suffering for hundreds of millions of people and claim more than 700,000 lives yearly. Diseases such as dengue, Zika, and chikungunya cause symptoms similar to malaria and are endemic in many parts…
- Conditions
- Dengue, Zika, Chikungunya
- Trial name
- NCT06595745
- Testing
- Wolbachia induced incompatible mating, Standard traditional chemical mosquito control
- Where
- Mexico
- Volunteers
- 15,243 people, healthy volunteers welcome
- Sponsor
- Michigan State University
Infectious Diseases
Sensitivity Study of Diagnostic for Early Detection of Dengue Infection
This study is a multi-site trial assessing the sensitivity of DENV Detect™ NS1 ELISA versus standard reference tests (e.g. PCR or viral culture) for dengue diagnosis in the US and internationally.
- Trial name
- NCT02059122
- Where
- 5 sites in Argentina, Barbados and 3 more
- Volunteers
- 911 people
- Sponsor
- InBios International, Inc.
Dengue Fever
Clinical Specimens Testing Program of Dengue Antigen Detection Reagents
Dengue virus serological reagent, included antigen and antiserum, is a serum test for identification of serum antibodies to dengue virus.
- Trial name
- NCT01917422
- Where
- Taiwan
- Volunteers
- 195 people, healthy volunteers welcome
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Dengue
ADVP005; Dengue CVD 12000 - Dengue-1-Virus Live Virus Human Challenge (DENV-1-LVHC)
The purpose of this research study is to test the protection of volunteers previously vaccinated with Tetravalent Dengue Virus (TDEN) Purified Inactivated Vaccine (PIV) with alum and boosted with TDEN live attenuated vaccine…
- Trial name
- NCT04786457
- Testing
- Dengue 1 Live Virus Human Challenge (DENV-1-LVHC)
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Dengue Vaccines
Passive Safety Surveillance Data of Dengue Vaccine, Qdenga (TAK 003) in Private Vaccination Sites in Buenos Aires, Argentina.
The TAK-003 vaccine, Qdenga, developed by Takeda, was approved by ANMAT in April 2023 and has been available in Argentina since November 2023 for individuals from 4 years old and without limit of age.
- Trial name
- NCT06898775
- Where
- Argentina
- Volunteers
- 112,345 people, healthy volunteers welcome
- Sponsor
- Fundación Vacunar
Dengue
A Controlled Human Infection Model of Dengue
This study aims to conduct a safe human infection challenge using an attenuated serotype DEN3 dengue virus in adult volunteers. The clinical, viral and immune response characteristics of the model will be analysed to understand…
- Trial name
- DEN-CHIM-01 (NCT07412483)
- Testing
- GMP-produced rDEN3delta30 virus
- Where
- Singapore
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Tan Tock Seng Hospital
Dengue Virus, Dengue Fever
Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Peruvian Children Aged 2 to 11 Years
The aim of the trial was to evaluate the use of a tetravalent vaccine, CYD dengue vaccine, against dengue disease. Primary Objectives: To describe the humoral immune response to dengue before and after each vaccination with…
- Conditions
- Dengue Virus, Dengue Fever, Dengue Hemorrhagic Fever, Dengue Diseases
- Trial name
- NCT00788151
- Testing
- CYD Dengue Vaccine Serotypes 1, 2, 3, and 4, Pneumococcal polysaccharide vaccine
- Where
- Peru
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Dengue Fever
Efficacy and Safety of Ivermectin Against Dengue Infection
This is a Phase II/III, Randomized, Double-Blind, Placebo-Controlled Study of Efficacy and Safety of Ivermectin in Children and Adult patients with Dengue Infection.
- Trial name
- NCT02045069
- Testing
- 2 days Ivermectin, 3 days Ivermectin
- Where
- Thailand
- Volunteers
- 360 people
- Sponsor
- Mahidol University